HF  AyurMaya




     Office Locations:

Bay Colony Corporate Center
1000 Winter Street, Suite 4500
Waltham, MA 02451
Phone: 781-522-4962

 

Stages:

  • Expansion
  • Growth


 

Industries:

  • Life Sciences & Healthcare

  •  

    Description:

    AyurMaya Capital Management Fund is a venture capital fund managed by Matrix Capital Management (see profile). Matrix Capital Management is an investment management firm which manages private investment funds in a concentrated portfolio of high conviction investments, primarily in public companies. Matrix Capital was co-founded in 1999 by David Goel.


     

    Funds:


      Fund Name


      Amount


      Date

    Get funds under management for this firm including Fund name, Dollar size of fund raise, and Vintage with a National Database subscription.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    David E. Goel Managing Partner

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      04/25/2024


      Endeavor BioMedicines


      CA


      $132,500,000


      Series C


      03/06/2024


      Alumis


      CA


      $259,000,000


      Series C


      09/19/2023


      ReCode Therapeutics


      TX


      $50,000,000


      Series B


      05/24/2023


      ElevateBio


      MA


      $401,000,000


      Series D


     

    Portfolio companies include:


      Acelyrin


      Alumis
        web link


      ElevateBio
        web link


      Endeavor BioMedicines
        web link


      Koneksa
        web link


      ReCode Therapeutics
        web link


     

    Recent News: